OrbiMed’s Glaukos GKOS Stock Holding History

OrbiMed’s Portfolio GKOS Stock Details GKOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,211,000	Closed	-$46.5M	–	150
2020 Q2	$46.5M	Sell	1,211,000 -336,646	-22%	-$12.5M	0.66%	47
2020 Q1	$47.8M	Hold	1,547,646	–	–	0.8%	38
2019 Q4	$84.3M	Buy	+1,547,646	New	+$94.2M	1.2%	29
2018 Q1	–	Sell	-836,500	Closed	-$21.5M	–	144
2017 Q4	$21.5M	Hold	836,500	–	–	0.27%	78
2017 Q3	$27.6M	Sell	836,500 -905,200	-52%	-$34.4M	0.26%	77
2017 Q2	$72.2M	Hold	1,741,700	–	–	0.76%	44
2017 Q1	$89.3M	Sell	1,741,700 -438,300	-20%	-$19.1M	1.01%	32
2016 Q4	$74.8M	Hold	2,180,000	–	–	0.95%	35
2016 Q3	$82.3M	Sell	2,180,000 -717,938	-25%	-$23.8M	0.94%	41
2016 Q2	$84.5M	Hold	2,897,938	–	–	0.88%	40
2016 Q1	$48.9M	Buy	2,897,938 +1	+0%	+$17	0.51%	49
2015 Q4	$71.5M	Hold	2,897,937	–	–	0.65%	44
2015 Q3	$70.1M	Hold	2,897,937	–	–	0.71%	42
2015 Q2	$84M	Buy	+2,897,937	New	+$84.2M	0.7%	43

Other funds holding GKOS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

OrbiMed's GKOS Position: Q3 2020 in Review

OrbiMed sold out of Glaukos (GKOS) in Q3 2020, closing a stake of 1,211,000 shares — an estimated $46.5M sold.

OrbiMed first reported a position in GKOS in Q2 2015 and held it in 14 quarters. The position peaked at $89.3M in Q1 2017. 178 funds tracked by Wall St. Rank hold GKOS as of Q3 2020.

OrbiMed reported no remaining Glaukos position as of Q3 2020 after selling out during the quarter.
OrbiMed sold 1,211,000 Glaukos shares in Q3 2020, an estimated $46.5M.
OrbiMed first reported a position in Glaukos in Q2 2015 and held it in 14 quarters.
OrbiMed's Glaukos position peaked at $89.3M in Q1 2017.
178 funds tracked by Wall St. Rank held Glaukos as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.